文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌全程新辅助治疗后等待观察策略的长期肛门直肠功能:横断面研究

Long-term anorectal function in rectal cancer patients managed by a watch-and-wait strategy after total neoadjuvant treatment: a cross-sectional study.
PubMed 文献 · Radiat Oncol · 2025-10-16

本研究评估全程新辅助治疗(TNT)后达到临床完全缓解(cCR)并采用等待观察(W&W)策略的直肠癌患者的长期肛门直肠功能与直肠毒性,并识别功能障碍的临床危险因素。单中心横断面研究纳入2014年12月至2020年11月间接受TNT后W&W的患者,要求至少随访2年且无疾病进展,采用多种量表评估。多数患者肛门直肠功能可接受,但排便急迫感常见,吸烟史是长期肛门直肠功能障碍的独立危险因素。

要点

  • TNT后W&W患者中,RTOG/EORTC≥II级晚期直肠毒性仅1.4%,无更严重毒性。
  • 排便急迫感最常见(60.0%),中位LARS评分16,主要LARS占15.7%。
  • 吸烟史是长期肛门直肠功能障碍的独立危险因素(OR 6.562)。

核心结论

  • 多数TNT后W&W的直肠癌患者长期肛门直肠功能可接受,但排便急迫感常见。
  • 吸烟史是长期肛门直肠功能障碍的独立危险因素。

研究设计与样本

  • 单中心横断面研究,纳入2014年12月至2020年11月接受TNT后W&W的直肠癌患者70例。
  • 要求至少随访2年且无疾病进展,中位随访43个月。
  • 采用半结构化访谈及RTOG/EORTC、LENT/SOMA、Wexner、LARS、MSKCC BFI量表评估。
  • 采用单因素分析和多因素Logistic回归识别肛门直肠功能障碍的危险因素。

主要发现

  • RTOG/EORTC标准下,I级晚期直肠毒性28/70(40.0%),II级1/70(1.4%),无更严重毒性。
  • 排便急迫感为最常见症状(42/70,60.0%)。
  • 中位LARS评分16(IQR 4-25),轻度LARS 17.1%(12/70),重度LARS 15.7%(11/70)。
  • 中位Wexner评分2(IQR 0-3),中位MSKCC BFI总分82.5(IQR 77-86)。
  • 吸烟史是长期肛门直肠功能障碍的独立危险因素(OR 6.562,95%CI 1.561-27.590)。

关键数值与推荐

  • RTOG/EORTC晚期直肠毒性分级:I级40.0%,II级1.4%,无≥III级。
  • LARS评分:中位16(IQR 4-25),轻度17.1%,重度15.7%。
  • Wexner评分中位2(IQR 0-3)。
  • MSKCC BFI总分中位82.5(IQR 77-86)。
  • 吸烟史OR 6.562(95%CI 1.561-27.590)。

临床怎么用

  • 对TNT后W&W患者应常规评估肛门直肠功能,关注排便急迫感。
  • 吸烟史可作为长期肛门直肠功能障碍的风险分层因素。
  • 功能评估可联合RTOG/EORTC、LARS、Wexner及MSKCC BFI等量表。

局限性

  • 单中心横断面设计,样本量70例,可能存在选择偏倚。
  • 需要更大规模的前瞻性研究聚焦肠道功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluates the long-term anorectal function and rectal toxicity in rectal cancer patients who achieved a clinical complete response (cCR) to total neoadjuvant treatment (TNT) and were managed with a watch-and-wait (W&W) approach. While oncological outcomes have been favorable, functional outcomes warrant further investigation. Additionally, this research identifies clinical risk factors of anorectal dysfunction post-treatment. METHODS: This was a single-center, cross-sectional study. Rectal cancer patients who underwent TNT followed by W&W between December 2014 and November 2020 were recruited. A minimum 2-year follow-up with no disease progression was required. The study took the form of semi-structured interviews. Multiple scales for evaluation were used, including the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale, the Late Effects of Normal Tissues/Subjective Objective Management Analytic (LENT/SOMA) system, the Wexner score, the Low Anterior Resection Syndrome (LARS) score and the Memorial Sloan Kettering Cancer Center Bowel Function Instrument (MSKCC BFI). Univariate analysis and multi-factor Logistic regression were used to identify the risk factors for anorectal dysfunction. RESULTS: Out of 70 patients with a median follow-up of 43 months, less than half experienced grade I (28/70, 40.0%) or II (1/70, 1.4%) late rectal toxicity according to the RTOG/EORTC criteria, with no cases of more severe toxicity. The prevalence of fecal urgency was the most significant symptom reported (42/70, 60.0%). The median LARS score was 16 [interquartile ranges (IQR) 4-25]; 17.1% (12/70) of patients had minor LARS and 15.7% (11/70) had major LARS. The median Wexner score was 2 (IQR 0-3). The median MSKCC BFI total score was 82.5 (IQR 77-86). Smoking history was an independent risk factor for long-term anorectal dysfunction [odds ratio (OR) 6.562, 95% confidence interval (CI) 1.561-27.590]. CONCLUSION: Most rectal cancer patients under a W&W strategy after TNT sustain acceptable anorectal function, though fecal urgency remains a common issue. Smoking history emerged as a significant risk factor for anorectal dysfunction. Larger prospective studies focusing on bowel function are needed.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu LY, Jin X, Zhang H, et al. Long-term anorectal function in rectal cancer patients managed by a watch-and-wait strategy after total neoadjuvant treatment: a cross-sectional study. Radiat Oncol. 2025. PMID: 41102815. doi:10.1186/s13014-025-02732-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。